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ABSTRACT 
Objective: To evaluate the immunogenicity and reactogenicity 
of two lots of a combined hepatitis A-hepatitis B va.ccine (HAV, 
HBV) in healthy 15 to 18 year olds. 
Design: This was a double-blind, randomized clinical study. 
Vaccine was administered into the deltoid at 0, 1, and 6 
months. lmmunogenicity was assessed by anti-HAV and anti- 
HBs antibody levels at 2, 6, and 7 months after the first vac- 
cine dose. Reactogenicity was assessed through use of 3-day 
diary cards following each vaccination, plus recclrding other 
unsolicited reactions. 
Results: A total of 160 adolescents were vaccinated; 155 who 
were seronegative for hepatitis A and B at baseline and who 
completed the study were included in the immunogenicity 
analysis. The vaccine was well tolerated; most side (effects were 
local, of low intensity and short duration. Good immunogenic- 
ity was determined by antibody titers. High rates of seroposi- 
tivity (99.4%) were achieved after two doses against HAV, and 
after three doses for anti-HBs (seroprotection = 913.7%). 
Conclusions: This combination vaccine will be useful for immu- 
nizing selected high-risk groups in developed countries. In 
countries where endemicity is low for both diseases, targeting 
students prior to risk of acquisition would be a feasible pre- 
ventive strategy. 
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Hepatitis A and hepatitis B are viral infections of the 
liver that affect large numbers of people worldwide. 
Poor living standards in the developing world facilitate 
transmission of hepatitis A virus (HAW), so infection usu- 
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ally occurs early in life and is generally subclinical; recov- 
ery leads to lifelong immunity. Improved standards of 
hygiene and sanitation decrease the early exposure to 
HAV leaving a large proportion of adolescents and adults 
susceptible to the infection.’ Disease is generally more 
severe in older individuals and may result in a prolonged 
convalescence. About 1.5% of adults develop disabling 
sequelae that persist over several months.2-4 Although 
HAV does not result in chronic liver disease, it can cause 
fulminant liver failure. 
Hepatitis B virus @IBV) is highly infectious and trans- 
mitted vertically, sexually, through parenteral exposure, 
and between children with close personal contact. In 
addition to morbidity and mortality similar to that asso- 
ciated with hepatitis A, HBV infection can persist and 
cause progressive chronic liver disease and cirrhosis. A 
substantial proportion of the global burden of primary 
liver cancer is attributable to chronic hepatitis B infection. 
Both diseases are endemic in many parts of the 
world, with hepatitis A (3 cases/1000 population) and 
hepatitis B (0.8 cases/lOOO) being among the most fre- 
quently occurring diseases in travellers against which 
immunization is available.5 Vaccination is the only pre- 
ventive method that confers long-term protection against 
hepatitis B and hepatitis A. Effective vaccines were intro- 
duced in the early 1980s and 1990s respectively. Hepati- 
tis B is the only sexually transmitted disease that can 
currently be prevented by vaccination. As there is over- 
lap in the high-risk groups for which these vaccines are 
currently recommended, and the same schedules for both 
vaccines can be used, there are obvious advantages in 
combining both within a single vaccination series. 
As well as vaccinating high-risk groups, there are 
compelling reasons to initiate immunization in infancy. 
Immunization against hepatitis A is espoused because of 
the role that mild or asymptomatic infection of children 
has in spread of the disease to caretakers and family mem- 
bers and because 50% of persons diagnosed have no iden- 
tifiable risk factor.6z7 A powerful argument for early 
hepatitis B immunization is the inverse relation between 
age at infection and development of the carrier state with 
associated sequelae. A combined vaccine would reduce 
the number of injections and hence the discomfort, 
thereby improving compliance with the recommended 
schedule. 
193 
194 International Journal of Infectious Diseases / Volume 2, Number 4, April-June 1998 
Subjects 
Local ethical approval and written informed consent were 
obtained prior to study entry from all participants as well 
as a parent or guardian. Healthy 15- to IS-year-old ado- 
lescents were recruited from six high schools. Accept- 
ability for enrollment was determined by medical 
examination, including physical examination and medical 
history, and serologic screening for study eligibility was 
undertaken within 14 days prior to entry into the study 
or by a blood sample taken at the time of study enroll- 
ment, immediately prior to the first vaccine dose. Exclu- 
sion criteria were positive titers for anti-HAV, anti-NBS, 
anti-HBc, or HBsAg at screening; previous vaccination 
against hepatitis A or B; elevated liver enzymes; a history 
of significant and persisting disease or chronic drug ther- 
apy; any acute illness; chronic alcohol consumption; 
hepatomegaly; right upper quadrant pain or tenderness; 
allergic reactions to previous vaccines; and simultaneous 
participation in any other clinical trial. 
Vaccine 
Two lots (HAB lOlD4; group 1: HAB 102A4; group 2) of 
a combined hepatitis A-hepatitis B vaccine (Twinrix”, 
SmithKline Beecham Biologicals, Rixensart, Belgium) were 
used. Each l.O-mL dose contained at least 720 enzyme- 
linked immunosorbent assay (ELISA) units of hepatitis A 
antigen and 20 pg of HBsAg adsorbed onto 0.5 mg of 
aIuminum (as aluminum salts), and was administered intra- 
muscularly into the deltoid at 0, 1, and 6 months. 
Serology 
Sera were prepared from blood drawn at 0, 1,2,6, and 7 
months. Initial baseline serologic screening was per- 
formed using standard diagnostic tests at the Victorian 
Infectious Diseases Reference Laboratory, Fairfield Hos- 
pital. Serum liver enzyme activities were measured using 
Beckman reagents. Antibodies against HAV were mea- 
sured using modified HAVAB (Abbott), HBsAg using 
AUSRIA II (Abbott), anti-H& by AUSAB (Abbott), and anti- 
HBc using CORAB (Abbott). Further measurements of 
anti-HAS7 at months 1,2, and 7 were undertaken at Clin- 
Lab (Genval, Belgium) using Enzymun ELISA (Boehringer 
Mannheim, Mannheim, Germany). Titers less than 
33 mIU/mL were considered seronegative, with an 
increase to 33 mIU/mL or higher considered as sero- 
conversion. Measurements of anti-HBs at months 1,2,6, 
and 7 were performed at SmithKIine Beecham Biologicals, 
using a commercial radioimmunoassay kit (AUSAB, 
Abbott). Subjects with anti-HBs antibody titers less than 
1 mIU/mL were considered seronegative with an increase 
to 1 mIU/mL or higher considered as a seroconversion 
and titers 10 mIU/mL or higher to be seroprotective. 
Reactogenicity 
On the day of each vaccination, and for 3 subsequent 
days, subjects recorded solicited local (soreness, redness, 
swelling) and general (oral temperature, headache, 
malaise, fatigue, nausea, vomiting) symptoms as either 
absent, mild, moderate, or severe (as defined in the pro- 
tocol), on a diary card. Any unsolicited local or general 
symptoms were also recorded. The relation between any 
experience reported and the study vaccine was assessed 
by the study investigator. 
Statistical Methods 
Fisher’s exact test was used to compare the incidence of 
local and general solicited symptoms after each dose. 
Geometric mean titers (GMTs) were calculated using the 
log transformation of values of seroconverters and then 
taking the anti-log of the mean of these transformed val- 
ues. Seroconversion rates and GMTs with 95% confidence 
intervals (CI) of anti-HBs and anti-HAS7 antibodies in sero- 
converters were calculated for all time points for which 
blood samples were taken. 
RESULTS 
Demographics 
The 160 volunteers enrolled and randomized to receive 
at least one dose of the two lots of vaccine were all 
included in the reactogenicity analysis. The mean age was 
16.4 years; there was no significant difference between 
groups. Five subjects were excluded from the immuno- 
genicity analysis: two from group 1 (one after dose one 
because of elevated liver enzymes at baseline and one 
with infectious mononucleosis at month 6) and three 
from group 2 (one because of anti-HBc seropositivity on 
the baseline blood sample, and two because of equivocal 
baseline anti-HBc results). 
Reactogenicity Analysis 
Following administration of 465 doses of vaccine, 464 
symptom sheets were returned (99.6% compliance). Over- 
all, the number of doses followed by a report of solicited 
or unsolicited symptoms was higher in group 1 than in 
group 2: 187/236 doses (79.2%) in group 1, and 167/238 
(70.2%) in group 2. Both groups reported more local than 
general symptoms: 69.5% of local versus 48.3% incidence 
of general symptoms and 61.8% versus 34.5%, in groups 
1 and 2, respectively. 
The incidence of local injection site symptoms did 
not increase significantly with successive doses in either 
group (Table 1). Soreness was the most frequently 
reported symptom in both groups, followed by redness 
and swelling. These reactions were consistently higher 
in group 1, significantly so for redness after dose one 
Table 1. Local and Systemic Adverse Reactions 
in the First 72 Hours after Vaccination 
Percentage of Subjects 
Reporting Symptoms* 
Adverse Reaction Dose Group 1 Group 2 All 
Any local reaction 
Soreness 
Redness 
Swelling 
Any systemic reaction 
Fever 
Headache 
Malaise 
Fatigue 
Nausea 
Vomiting 
2 
3 
2 
3 
2 
3 
2 
3 
Overall 
1 
2 
3 
2 
3 
2 
3 
65.8 67.5 
67.1 63.3 
69.2 54.4 
69.5 61.8 
62.0 61.3 
63.3 58.2 
60.0 48.1 
45.6 23.8 
29.1 20.3 
34.6 20.3 
21.5 11.3 
21.5 15.2 
26.9 13.9 
58.2 45.0 
45.6 30.4 
41 .o 27.8 
48.3 34.5 
2.5 0.0 
2.5 0.0 
5.1 2.5 
30.4 22.5 
21.5 19.0 
14.1 15.2 
10.1 8.8 
6.3 8.9 
3.8 6.3 
39.2 27.5 
30.4 17.7 
26.9 19.0 
13.9 10.0 
10.1 5.1 
10.3 3.8 
3.8 1.3 
1.3 I .3 
0.0 0.0 
66.7 
65.2 
61.4 
65.6 
62.4 
60.7 
54.1 
24.6 
24.6 
27.3 
16.5 
18.3 
20.3 
51.6 
38.0 
34.4 
41.4 
2.5 
2.5 
3.8 
26.4 
20.2 
14.6 
9.4 
7.5 
5.0 
33.3 
24.0 
23.6 
11.9 
7.5 
7.0 
2.5 
1.3 
0.0 
*Numbers of people in the reactogenicity analysis: 
Group 1: dose 1 = 79; dose 2 = 79; dose 3 = 78; total number of injections = 236. 
Group 2: dose 1 = 80; dose 2 = 79; dose 3 = 79; total number of injections = 238. 
(P = 0.005) and swelling following dose three (F’ = 0.05). 
The incidence of local side effects reported on more than 
1 consecutive day was also higher in group 1. All local 
solicited symptoms resolved without intervention, within 
the 3-day follow-up period in all but four cases. 
General Signs and Symptoms 
Fatigue was the most commonly reported general symp- 
tom in both groups after each dose, followed by headache 
and nausea, whereas fever and vomiting occurred rarely. 
There was a trend for more general solicited symptoms 
in group 1, but there was no significant difference 
between the two groups following any dose. AU solicited 
general symptoms resolved within the 3-day follow-up 
period, except for one subject who had symptoms of 
nausea, fatigue, and malaise that resolved on day 4 fol- 
lowing dose three. Most solicited general events were 
considered to be possibly related to vaccination (83.1% 
group 1,77.6% group 2). There were no serious adverse 
events associated with the vaccination. 
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Table 2. Seropositivity Rates and Geometric Mean 
Titers (GMT) of Anti-HAV Antibody Titers of Seroconverters 
Seropositive GMT 
Group Timing n n (%j mlU/mL (95% Cl) 
1 Post dose 1,l mo 78 72 (92.3) 254 (205-315) 
Post dose 2,2 mo 78 78 (100.0) 574 (480-687) 
Post dose 2,6 mo 77 77 (100.0) 307 (252-373) 
Post dose 3, 7 mo 78 78 (100.0) 5694 (4798-6756) 
2 Post dose 1, 1 mo 76 68 (89.5) 221 (178-276) 
Post dose 2, 2 mo 75 74 (98.7) 665 (531-834) 
Post dose 2, 6 mo 77 75 (97.4) 377 (304-468) 
Post dose 3, 7 mo 77 77 (100.0) 6260 (5158-7598) 
Immunogenicity: Hepatitis A 
Seropositivity and geometric mean anti-HAV antibody 
titers are presented in Table 2, showing that 1 month 
after doses one and two, 90.9% and 99.3% of the subjects 
had seroconverted for anti-H& respectively. Four months 
later, prior to dose three, 98.7% of subjects remained 
seropositive, increasing to 100% one month after booster 
vaccination with 9.9 and 9.4-fold increases in GMTs over 
month 2, respectively. 
Immunogenicity: Hepatitis B 
The seropositivity rates and GMT of anti-HBs antibody 
titers are presented in Table 3. One month after the sec- 
ond dose of vaccine, 89.7% and 97.3% of subjects in 
groups 1 and 2, respectively, were seropositive with 
respect to anti-HBs antibodies, which increased to 97.4% 
and 100.0% four months later before booster vaccination, 
with a corresponding increase in GMTs. One month after 
the booster, all subjects except one had seroconverted, 
with l&fold and 21-fold increases in GMTs for groups 1 
and 2, respectively. 
CONCLUSIONS 
This double-blind, randomized trial found two lots of com- 
bined hepatitis A-hepatitis B (SmithKline Beecham Bio- 
logicals) vaccine to be safe and highly immunogenic in 
healthy adolescent volunteers aged 15 to 18 years. The 
Table 3. Seropositivity Rates and Geometric Mean Titers (GMT) 
of Anti-HBs Antibody Titers of Seroconverters 
Seropositive GMT 
Group Timing n n f%l mlU/mL (95% Cl) 
1 Post dose 1, 1 mo 78 43 (55.1) 13 (8-21) 
Post dose 2,2 mo 78 70 (89.7) 29 (20-41) 
Post dose 2,6 mo 77 75 (97.4) 238 (175-324) 
Post dose 3, 7 mo 78 77 (98.7) 4316 (3011-6185) 
2 Post dose 1, 1 mo 76 42 (55.3) 11 (7-l 8) 
Post dose 2,2 mo 75 73 (97.3) 25 (18-34) 
Post dose 2, 6 mo 77 77 (100.0) 214 (154-298) 
Post dose 3, 7 mo 77 77 (100.0) 4436 (3205-6141) 
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vaccines were well tolerated; side effects were generally 
mild in intensity and short-lived, and there were no seri- 
ous adverse events related to vaccine administration. There 
were no clinically significant differences in local or sys- 
temic reactions between the two vaccine lots at any dose. 
The vaccine was highly immunogenic, as determined 
by antibody titers. One month after dose two, all but one 
subject had seroconverted with respect to hepatitis A, 
and the seroconversion rate for anti-HBs was 89.7% for 
group 1 and 97.3% for group 2. Interestingly, between 
months 2 and 6, the GMT and seropositivity rate for anti- 
HBs increased. After the booster dose, all subjects had 
seroconverted for both antigens, except one individual in 
group 1 who remained seronegative for anti-HBs. 
There are several advantages to combining hepatitis 
A and B vaccination, which include convenience, patient 
acceptance, compliance, and savings in the cost of pack- 
aging and administration. The performance of this com- 
bination vaccine supports its use in immunizing high-risk 
groups, but it also is appropriate to consider whether it 
could have a role in general population health programs. 
The lack of success of selective vaccination programs tar- 
geting those at high risk of hepatitis B in preventing ongo- 
ing transmission of infection has caused many countries 
to implement universal hepatitis B vaccination programs, 
either in infants or in adolescents.8 The appropriate time 
or age at which to deliver prophylactic vaccines is deter- 
mined by the epidemiology of the infection, since vac- 
cines must be given prior to exposure. 
Adolescence is a time of transition, and the quest for 
independence involves risk taking. Developmental char- 
acteristics of adolescents make sexually transmissible dis- 
eases a concern for youths, because their sexual behavior 
can include sexual experimentation, multiple partnering, 
and inconsistent condom use.9 Sexually transmitted dis- 
eases, including hepatitis B, have their highest incidence 
in older teens and young adults, and other risk taking 
behavior, such as injection drug use, skin piercing, and tat- 
tooing may commence at this time.Young adult life also 
is the time when occupational risk of infection may begin 
and when youth undertake periods of travel overseas, 
often backpacking or living cheaply for many months in 
countries where hepatitis A infections are endemic. 
Widespread use of a combined hepatitis A and B vac- 
cine depends in part upon the epidemiology of the two 
diseases in various regions. For developed countries with 
low hepatitis A and B endemicity, such as Australia, the 
United States, and many countries in Europe, early ado- 
lescence is an appropriate time at which to offer com- 
bined hepatitis A and B vaccination, since it precedes the 
time when most individuals are at-risk of these diseases 
through lifestyle, occupation, or travel. In spite of the 
decline in the incidence of hepatitis A in the developed, 
and some developing countries, because of the increased 
number of nonimmune individuals in the population, out- 
breaks will remain inevitable, particularly due to travellers 
returning from endemic areas. Where endemicity is low 
for both diseases, targeting students prior to risk of acqui- 
sition would be one preventive strategy, and school may 
be an efficient place at which to provide mass vaccination. 
However, considerations such as the desired level of pre- 
vention, the costs and benefits of vaccination, program- 
matic considerations, and the operational feasibility of a 
vaccination strategy are important in developing immu- 
nization recommendations. 
The development of new effective and safe vaccines 
is an important step in the global eradication of conta- 
gious diseases. Combined vaccine products will eventu- 
ally make immunization schedules more cost-effective 
and improve compliance rates.” As more countries adopt 
universal infant or adolescent hepatitis B vaccination, the 
possibility of concurrent vaccination against hepatitis A, 
through the use of a combined vaccine may be consid- 
ered,‘l since it is recognized that hepatitis A is now a 
vaccine-preventable disease, and one for which global 
eradication is possible. 
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